The dermatological drugs market in Italy is expected to reach a projected revenue of US$ 2,222.4 million by 2033. A compound annual growth rate of 12% is expected of Italy dermatological drugs market from 2026 to 2033.
The Italy dermatological drugs market generated a revenue of USD 903.6 million in 2025 and is expected to reach USD 2,222.4 million by 2033.
The Italy market is expected to grow at a CAGR of 12% from 2026 to 2033.
In terms of segment, psoriasis was the largest revenue generating indication in 2025.
Psoriasis is the most lucrative indication segment registering the fastest growth during the forecast period.
Dermatological drugs market data book summary
Market revenue in 2025
USD 903.6 million
Market revenue in 2033
USD 2,222.4 million
Growth rate
12% (CAGR from 2026 to 2033)
Largest segment
Psoriasis
Fastest growing segment
Psoriasis
Historical data
2021 - 2024
Base year
2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Acne, Alopecia, Psoriasis, Rosacea
Key market players worldwide
AbbVie Inc, Pfizer Inc, GSK PLC ADR, Sun Pharmaceutical Industries, GALDERMA, Amgen Inc, Johnson & Johnson Services, Inc., Novartis AG ADR, Eli Lilly and Co, Almirall SA, Bausch Health Companies Inc
Other key industry trends
In terms of revenue, Italy accounted for 3.5% of the global dermatological drugs market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, Germany dermatological drugs market is projected to lead the regional market in terms of revenue in 2033.
Sweden is the fastest growing regional market in Europe and is projected to reach USD 607.8 million by 2033.
The dermatological drugs market in Italy is expanding, driven by the rising prevalence of skin conditions such as acne, eczema, and psoriasis. Additionally, there is growing demand for aesthetic dermatology treatments. These factors, coupled with Italy's aging population, are increasing the demand for therapies targeting age-related skin issues. The country’s healthcare infrastructure supports the availability of prescription-based and over-the-counter dermatological products, enhancing market accessibility.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Dermatological Drugs Market Outlook will help companies and investors design strategic landscapes.
Psoriasis was the largest segment with a revenue share of 39.45% in 2025.
Horizon Databook has segmented the Italy dermatological drugs market based on acne, alopecia, psoriasis, rosacea covering the revenue growth of each sub-segment from 2021 to 2033.
The dermatological drugs market in Italy is expanding, driven by the rising prevalence of skin conditions such as acne, eczema, and psoriasis. Additionally, there is growing demand for aesthetic dermatology treatments. These factors, coupled with Italy's aging population, are increasing the demand for therapies targeting age-related skin issues. The country’s healthcare infrastructure supports the availability of prescription-based and over-the-counter dermatological products, enhancing market accessibility.
Italy Dermatological Drugs Market Indication Outlook (Revenue, USD Million , 2021-2033)
Psoriasis
Atopic Dermatitis (Eczema)
Fungal infections
Acne
Alopecia
Rosacea
Others
Italy Dermatological Drugs Market Type Outlook (Revenue, USD Million , 2021-2033)
Prescription
Over-the-Counter (OTC)
Italy Dermatological Drugs Market Route of Administration Outlook (Revenue, USD Million , 2021-2033)
Topical Administration
Oral Administration
Parenteral Administration
Italy Dermatological Drugs Market Drug Class Outlook (Revenue, USD Million , 2021-2033)
Corticosteroids
Retinoids
Antibiotics
Antifungals
Calcineurin Inhibitors
Others
Italy Dermatological Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Others
Reasons to subscribe to Dermatological Drugs Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Dermatological Drugs Market Outlook databook
Our clientele includes a mix of Dermatological Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy Dermatological Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Italy Dermatological Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.